{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:27:39Z","timestamp":1778718459048,"version":"3.51.4"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["T32 DA 7242-23"],"award-info":[{"award-number":["T32 DA 7242-23"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug and Alcohol Dependence"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.drugalcdep.2018.06.015","type":"journal-article","created":{"date-parts":[[2018,7,24]],"date-time":"2018-07-24T15:54:07Z","timestamp":1532447647000},"page":"229-234","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Study characteristics influence the efficacy of substance abuse treatments: A meta-analysis of medications for alcohol use disorder"],"prefix":"10.1016","volume":"190","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7985-0870","authenticated-orcid":false,"given":"Elias M.","family":"Klemperer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John R.","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shelly","family":"Naud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.drugalcdep.2018.06.015_bib0005","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1176\/appi.ajp.2013.12030315","article-title":"Meta-regression analysis of placebo response in antipsychotic trials, 1970-2010","volume":"170","author":"Agid","year":"2013","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.drugalcdep.2018.06.015_bib0010","series-title":"Randomised Controlled Trial of Acamprosate Versus Placebo in Swedish Alcoholics","author":"Borg","year":"2003"},{"key":"10.1016\/j.drugalcdep.2018.06.015_bib0015","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1111\/j.1530-0277.2009.01024.x","article-title":"A randomized, double\u2010blind, placebo\u2010controlled pilot study of naltrexone in outpatients with bipolar disorder and alcohol dependence","volume":"33","author":"Brown","year":"2009","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.1016\/j.drugalcdep.2018.06.015_bib0020","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1111\/acer.12067","article-title":"The declining efficacy of naltrexone pharmacotherapy for alcohol use disorders over time: a multivariate meta-analysis","volume":"37","author":"Del Re","year":"2013","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.1016\/j.drugalcdep.2018.06.015_bib0025","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/JCP.0b013e3182983e73","article-title":"Placebo group improvement in trials of pharmacotherapies for alcohol use disorders: a multivariate meta-analysis examining change over time","volume":"33","author":"Del Re","year":"2013","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.drugalcdep.2018.06.015_bib0030","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s13063-017-1872-0","article-title":"The association of funding source on effect size in randomized controlled trials: 2013-2015 \u2013 a cross-sectional survey and meta-analysis","volume":"18","author":"Falk Delgado","year":"2017","journal-title":"Trials"},{"key":"10.1016\/j.drugalcdep.2018.06.015_bib0035","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1111\/j.1360-0443.2007.01822.x","article-title":"The impact of pharmaceutical company funding on results of randomized trials of nicotine replacement therapy for smoking cessation: a meta-analysis","volume":"102","author":"Etter","year":"2007","journal-title":"Addiction"},{"key":"10.1016\/j.drugalcdep.2018.06.015_bib0040","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1097\/01.ALC.0000171061.03686.BC","article-title":"Does effect size in naltrexone trials for alcohol dependence differ for single-site vs. multi-center studies?","volume":"29","author":"Feinn","year":"2005","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.1016\/j.drugalcdep.2018.06.015_bib0045","series-title":"The Handbook of Research Synthesis.","article-title":"Measures of effect size for categorical data","author":"Fleiss","year":"1994"},{"key":"10.1016\/j.drugalcdep.2018.06.015_bib0050","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.conb.2013.05.005","article-title":"Pharmacotherapy for alcohol dependence: status of current treatments","volume":"23","author":"Franck","year":"2013","journal-title":"Curr. Opin. Neurobiol."},{"key":"10.1016\/j.drugalcdep.2018.06.015_bib0055","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1186\/2193-1801-3-740","article-title":"The effect size, study design, and development experience in commercially sponsored studies for new drug applications in approved drugs","volume":"3","author":"Fukunaga","year":"2014","journal-title":"Springerplus"},{"key":"10.1016\/j.drugalcdep.2018.06.015_bib0060","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1001\/jama.293.13.1617","article-title":"Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial","volume":"293","author":"Garbutt","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.drugalcdep.2018.06.015_bib0065","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1471-2288-6-25","article-title":"The fading of reported effectiveness. A meta-analysis of randomised controlled trials","volume":"6","author":"Gehr","year":"2006","journal-title":"BMC Med. Res. Methodol."},{"key":"10.1016\/j.drugalcdep.2018.06.015_bib0070","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1111\/j.1360-0443.2010.03155.x","article-title":"Industry funding and placebo quit rate in clinical trials of nicotine replacement therapy: A commentary on Etter et al. (2007)","volume":"105","author":"Greene","year":"2010","journal-title":"Addiction"},{"key":"10.1016\/j.drugalcdep.2018.06.015_bib0075","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1111\/j.1360-0443.2010.02964.x","article-title":"Commentary on Smolkowski et al., 2010): why is it important to assume that non\u2010responders in tobacco cessation trials have relapsed?","volume":"105","author":"Hajek","year":"2010","journal-title":"Addiction"},{"key":"10.1016\/j.drugalcdep.2018.06.015_bib0080","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1080\/14622200110050411","article-title":"Statistical analysis of randomized trials in tobacco treatment: longitudinal designs with dichotomous outcome","volume":"3","author":"Hall","year":"2001","journal-title":"Nicotine Tob. Res."},{"key":"10.1016\/j.drugalcdep.2018.06.015_bib0085","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1176\/appi.ajp.161.11.2045","article-title":"Research design features and patient characteristics associated with the outcome of antidepressant clinical trials","volume":"161","author":"Khan","year":"2004","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.drugalcdep.2018.06.015_bib0090","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD006266.pub2","article-title":"Gamma-hydroxybutyrate (GHB) for treatment of alcohol withdrawal and prevention of relapses","author":"Leone","year":"2010","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.drugalcdep.2018.06.015_bib0095","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1111\/acer.12197","article-title":"The placebo effect in clinical trials for alcohol dependence: An exploratory analysis of 51 naltrexone and acamprosate studies","volume":"37","author":"Litten","year":"2013","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.1016\/j.drugalcdep.2018.06.015_bib0100","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.MR000033.pub3","article-title":"Industry sponsorship and research outcome","author":"Lundh","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.drugalcdep.2018.06.015_bib0105","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1360-0443.2012.04054.x","article-title":"Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: When are these medications most helpful?","volume":"108","author":"Maisel","year":"2013","journal-title":"Addiction"},{"key":"10.1016\/j.drugalcdep.2018.06.015_bib0110","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.c869","article-title":"CONSORT 2010 explanation and elaboration: updated guidelines for reporting parellel group rendomised trials","volume":"340","author":"Moher","year":"2010","journal-title":"Br. Med. J."},{"key":"10.1016\/j.drugalcdep.2018.06.015_bib0115","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1007\/s00787-003-0327-1","article-title":"Acamprosate and its efficacy in treating alcohol dependent adolescents","volume":"12","author":"Niederhofer","year":"2003","journal-title":"Eur. Child Adolesc. Psychiatry"},{"key":"10.1016\/j.drugalcdep.2018.06.015_bib0120","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD008544.pub2","article-title":"Anticonvulsants for alcohol dependence","author":"Pani","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.drugalcdep.2018.06.015_bib0125","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.euroneuro.2008.08.009","article-title":"Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD","volume":"19","author":"Papakostas","year":"2009","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.drugalcdep.2018.06.015_bib0130","article-title":"Acamprosate for alcohol dependence","author":"Rosner","year":"2010","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.drugalcdep.2018.06.015_bib0135","article-title":"Opioid antagonists for alcohol dependence","author":"Rosner","year":"2010","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.drugalcdep.2018.06.015_bib0140","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1159\/000209348","article-title":"Does study design influence outcome? The effects of placebo control and treatment duration in antidepressant trials","volume":"78","author":"Rutherford","year":"2009","journal-title":"Psychother. Psychosom."},{"key":"10.1016\/j.drugalcdep.2018.06.015_bib0145","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1111\/j.1360-0443.2009.02896.x","article-title":"Modeling missing binary outcome data in a successful web-based smokeless tobacco cessation program","volume":"105","author":"Smolkowski","year":"2010","journal-title":"Addiction"},{"key":"10.1016\/j.drugalcdep.2018.06.015_bib0150","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1136\/bmj.323.7304.101","article-title":"Systematic reviews in health care: investigating and dealing with publication and other biases in meta-analysis","volume":"323","author":"Sterne","year":"2001","journal-title":"BMJ"},{"key":"10.1016\/j.drugalcdep.2018.06.015_bib0155","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.1111\/acer.12543","article-title":"Methods to analyze treatment effects in the presence of missing data for a continuous heavy drinking outcome measure when participants drop out from treatment in alcohol clinical trials","volume":"38","author":"Witkiewitz","year":"2014","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.1016\/j.drugalcdep.2018.06.015_bib0160","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1017\/S1461145710001641","article-title":"Factors modifying drug and placebo responses in randomized trials for bipolar mania","volume":"14","author":"Yildiz","year":"2011","journal-title":"Int. J. Neuropsychopharmacol."}],"container-title":["Drug and Alcohol Dependence"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871618303764?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871618303764?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,23]],"date-time":"2019-09-23T08:36:58Z","timestamp":1569227818000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0376871618303764"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":32,"alternative-id":["S0376871618303764"],"URL":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2018.06.015","relation":{},"ISSN":["0376-8716"],"issn-type":[{"value":"0376-8716","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Study characteristics influence the efficacy of substance abuse treatments: A meta-analysis of medications for alcohol use disorder","name":"articletitle","label":"Article Title"},{"value":"Drug and Alcohol Dependence","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2018.06.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}